摘要
目前在全球范围内肺癌已成为发病率和死亡率增长最快、严重危害人类健康和生命的恶性肿瘤之一。在我国肺癌病死率已居肿瘤死亡率首位,其中非小细胞肺癌(NSCLC)约占肺癌的80%以上,且多数患者确诊时已属晚期,因此内科治疗仍是肺癌的主要治疗方法。但近十年来以化疗为主的治疗手段并未使非小细胞肺癌的疗效获得突破性进展。20世纪90年代以来,关于肺癌的分子靶向治疗研究不断深入,其中以表皮生长因子受体和肿瘤血管生成作为靶点的药物为主,部分药物已经在晚期NSCLC治疗中显示出较好的临床疗效。21世纪分子靶向治疗已取得了飞跃的进展,许多新的靶向性治疗研究为NSCLC治疗提供新的治疗途径。本研究将从以表皮生长因子受体为靶点药物,抗肿瘤血管生成药物以及多靶点抗肿瘤药物3个方面就目前非小细胞肺癌靶向治疗的研究进展作一介绍。
At present, lung cancer is one of the malignant tumors with the highest morbidity and mortality rates. In China, lung cancer ranks first in terms of mortality from malignant tumors. In addition, the incidence of non-small-cell lung cancer （NSCLC） is over 80% among all lung cancers. Most NSCLC cases are diagnosed in the advanced stage, so medical treatment remains the primary therapy for NSCLC. Over the past 10 years, however, chemotherapy, as a first-line therapy, has failed to progress in terms of curative effects against NSCLC. Since the 1990s, with intensified studies on molecular-targeted therapy for lung cancer, where epidermal growth factor receptor （EGFR） and tumor angiogenesis became therapeutic targets, some drugs have shown satisfactory clinical effects in the treatment of advanced NSCLC. In the 21st century, research on molecular-targeted therapy has greatly developed, and studies on several novel targeted therapies have provided new modes of treatment for NSCLC. In the present article, the progress in targeted therapy for NSCLC is introduced based on three aspects： drugs that target EGFR, tumor angiogenesis, and multi-target antitumor drugs.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2011年第15期927-930,共4页
Chinese Journal of Clinical Oncology
基金
supported by the Natural Science Foundation of Tianjin Medical University(No.2008ky21)
the Tianjin Cancer Institute and Hospital(No.0906)
关键词
非小细胞肺癌
分子靶向治疗
表皮生长因子受体
Non-small-cell lung cancer
Molecular targeted therapy
Epidermal growth factor receptor
